TY -的T1 -β受体阻滞剂在肺动脉hypertension: evolving concepts of right heart failure JF - European Respiratory Journal JO - Eur Respir J SP - 619 LP - 621 DO - 10.1183/09031936.00051215 VL - 46 IS - 3 AU - de Man, Frances S. AU - Handoko, M. Louis Y1 - 2015/09/01 UR - //www.qdcxjkg.com/content/46/3/619.abstract N2 - Current guidelines advise against the use of β-blockers in pulmonary arterial hypertension (PAH) to avoid systemic hypotension [1]. In addition, PAH patients have a fixed stroke volume, and are therefore highly dependent on heart rate to increase their cardiac output [2–4]. Indeed, Provencher et al. [5] showed that withdrawal of β-blockers significantly improved exercise capacity in portopulmonary hypertension. Peacock and Ross [6] described another case of portopulmonary hypertension, in which the use of a β-blocker to treat a supraventricular tachycardia in an already haemodynamically unstable patient was nearly fatal.Beta-blockers can be used safely by some PAH patients with comorbidities such as arrhythmias or hypertension http://ow.ly/P2JHg ER -